Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Transkaryotic(tktx) -- Ignore unavailable to you. Want to Upgrade?

To: Souze who wrote (98)	10/23/2001 12:11:03 PM
From: Souze	Respond to of 122

TKT Awarded U.S. Patent Relating to Protein Production and Delivery For Gene Therapy CAMBRIDGE, Mass., Oct 23, 2001 /PRNewswire via COMTEX/ -- Transkaryotic Therapies, Inc. (Nasdaq: TKTX chart, msgs) today announced that the U.S. Patent and Trademark Office has issued Patent No. 6,303,379 entitled, "In Vivo Protein Production and Delivery System for Gene Therapy." The patent covers the transfection of cells relating to the delivery of therapeutic proteins. This technology offers several advantages to conventional gene therapy approaches including safety, ease of administration, dose precision, and cost effectiveness. "The issuance of this patent further strengthens TKT's intellectual property portfolio in the area of non-viral gene therapy," said Mary S. Consalvi, Vice President and Chief Intellectual Property Counsel at TKT. "Utilizing this novel technology, we have the potential to treat a variety of human diseases and conditions, among them anemia, diabetes, hemophilia, hypercholesterolemia, and multiple sclerosis, through the production and delivery of therapeutic proteins." A copy of the patent described above is available on the World Wide Web at uspto.gov. --- snipped ---